These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2698471)

  • 1. Immunotoxins, ligand-toxin conjugates and molecular targeting.
    Soria M
    Pharmacol Res; 1989; 21 Suppl 2():35-46. PubMed ID: 2698471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins.
    Giansanti F; Flavell DJ; Angelucci F; Fabbrini MS; Ippoliti R
    Toxins (Basel); 2018 Feb; 10(2):. PubMed ID: 29438358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
    J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer.
    Weidle UH; Tiefenthaler G; Schiller C; Weiss EH; Georges G; Brinkmann U
    Cancer Genomics Proteomics; 2014; 11(1):25-38. PubMed ID: 24633317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleotide sequence of cDNA coding for saporin-6, a type-1 ribosome-inactivating protein from Saponaria officinalis.
    Benatti L; Saccardo MB; Dani M; Nitti G; Sassano M; Lorenzetti R; Lappi DA; Soria M
    Eur J Biochem; 1989 Aug; 183(2):465-70. PubMed ID: 2547612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on ribosome-inactivating proteins from Saponaria officinalis.
    Soria MR; Benatti L; Nitti G; Ceriotti A; Solinas M; Lappi DA; Lorenzetti R
    Targeted Diagn Ther; 1992; 7():193-212. PubMed ID: 1633290
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotoxins in cancer therapy: Review and update.
    Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
    Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotoxins: is there a clinical value?
    Gottstein C; Winkler U; Bohlen H; Diehl V; Engert A
    Ann Oncol; 1994; 5 Suppl 1():97-103. PubMed ID: 7826425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotoxins containing single-chain ribosome-inactivating proteins.
    Lambert JM; Blättler WA; McIntyre GD; Goldmacher VS; Scott CF
    Cancer Treat Res; 1988; 37():175-209. PubMed ID: 2908625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotoxins and cytokine toxin fusion proteins.
    Strom TB; Anderson PL; Rubin-Kelley VE; Williams DP; Kiyokawa T; Murphy JR
    Semin Immunol; 1990 Nov; 2(6):467-79. PubMed ID: 2104283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular action of the type 1 ribosome-inactivating protein saporin 5 on Vicia sativa ribosomes.
    Iglesias R; Arias FJ; Rojo MA; Escarmis C; Ferreras JM; Girbés T
    FEBS Lett; 1993 Jul; 325(3):291-4. PubMed ID: 8319810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of immunotoxins for the therapy of cancer, AIDS, and immune dysfunctions.
    Vitetta ES
    Princess Takamatsu Symp; 1988; 19():333-40. PubMed ID: 3077626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant targeted proteins for biotherapy.
    Ahmad A; Law K
    Mol Biother; 1990 Jun; 2(2):67-73. PubMed ID: 2194500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
    Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
    Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotoxins and cancer therapy.
    Li Z; Yu T; Zhao P; Ma J
    Cell Mol Immunol; 2005 Apr; 2(2):106-12. PubMed ID: 16191416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
    Rosenblum MG; Marks JW; Cheung LH
    Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotoxins: a clinical review of their use in the treatment of malignancies.
    Hertler AA; Frankel AE
    J Clin Oncol; 1989 Dec; 7(12):1932-42. PubMed ID: 2685183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxin-labeled monoclonal antibodies.
    Kreitman RJ
    Curr Pharm Biotechnol; 2001 Dec; 2(4):313-25. PubMed ID: 11762413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diphtheria-related peptide hormone gene fusions: a molecular genetic approach to chimeric toxin development.
    Murphy JR
    Cancer Treat Res; 1988; 37():123-40. PubMed ID: 2908622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant toxins for the treatment of cancer.
    Kreitman RJ
    Curr Opin Mol Ther; 2003 Feb; 5(1):44-51. PubMed ID: 12669470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.